explore -WSS

explore

author：hotspot 2025-10-01 10:51:52 - browse：63

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Wikipedia

hotspot

WSS

Biden tests positive for Covid

Google and Epic fight stronger regulation of AI in health care

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

When a patient nears the end, a feared therapy can comfort

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Biden tests positive for Covid

Wikipedia

explore

leisure time

Peter Hotez and the public health issue of online harassment

AI can’t replace a physician’s gut feeling

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

How dance can help nurses traumatized by Covid

Psychedelics group wrestles with new pharma identity

WHO calls for emergency meeting on new China virus, as cases spread

Trump demands the U.S. pay no more for drugs than other countries … again

Startup Neumora takes a novel depression drug to Phase 3

Activists slam private health insurers over coverage restrictions

Judge denies Trump's request for new trial in E. Jean Carroll case

focus

A new ‘biological computer' targets cancer while sparing healthy cells

Cosmetics set for new safety regulation. Why the industry is on board

Key House panel plots a new health care package

Why hospitals are withdrawing from US News rankings

When a patient nears the end, a feared therapy can comfort

How dance can help nurses traumatized by Covid

Wikipedia

Wikipedia

hotspot

entertainment